You would like to know more about the topic of Thalidomide? Then make use of this link


The Development – Grünenthal Group

2012 Palexia® is available in UK, Spain, Italy, Denmark, Sweden, Ireland, Portugal, Norway, Belgium and Switzerland.
2011 FDA approval and launch of Tapentadol ER for chronic pain.
2011 Market introduction in the United States of INTAC®, an innovative formulation technology for the protection of intended drug action.
2010 Marketing authorization  of Tapentadol IR and PR in 26 EU countries
2009 EU submission of Tapentadol for acute and chronic pain, launch of Nucynta® in the US by Johnson & Johnson
2008 Approval of Tapentadol in the US
since 2004 Broad investments in R&D and late clinical trials
since 2000 Global launches (Zaldiar®, Transtec®)
Since 1990 Increasing internationalization of Grünenthal through local founding of subsidiaries and aquisitions
1979 Expansion of the Latin America business through founding of subsidiaries in Columbia and Chile
1977 Tramal® launched – worldwide partnering
1968 First international activities
1957 Launch of Thalidomide (withdrawn from market in 1961)
1947 Registration of Penicillin
1946 Hermann Wirtz founded Chemie Grünenthal GmbH